Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
A new deal cuts R21/Matrix-M malaria vaccine costs, enabling Gavi to deliver 30 million more doses and protect 7 million more children by 2030.
A new pricing agreement has slashed the cost of the R21/Matrix-M malaria vaccine, allowing Gavi to secure 30 million more doses by 2030 and protect 7 million additional children.
Funded by an advance payment from IFFIm, the deal saves up to $90 million and accelerates access in high-burden African countries.
Over 40 million doses have already been delivered across 24 nations, with 14 more countries introducing the vaccine in 2024 and seven in 2025.
Both WHO-recommended malaria vaccines reduce cases by over 50% in the first year, with booster doses providing lasting protection.
The expansion brings Gavi closer to its 2030 goal of vaccinating 50 million more children, offering immediate life-saving benefits amid shrinking global aid.
Un nuevo acuerdo reduce los costos de la vacuna contra la malaria R21/Matrix-M, lo que permite a Gavi suministrar 30 millones de dosis más y proteger a 7 millones de niños más para 2030.